Allopregnanolone (Zuranolone) in Post-stroke Depression

Summary

The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are: Is zuranolone safe to take by participants who have moderate to severe post-stroke depression? Is zuranolone well-tolerated by participants who have moderate to severe post-stroke depression? Does zuranolone treat moderate to severe post-stroke depression?

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Post Stroke Depression

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

21 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Duke University

Last updated on ClinicalTrials.gov

September 3, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites